First quarter results to be discussed at the company's annual and
special meeting of shareholders which will be Webcast live with question and answer
TORONTO, Feb. 21 /CNW/ - Patheon Inc. (TSX: PTI), a leading provider of
contract development and manufacturing services to the global
pharmaceutical industry, announced today that it will report its first
quarter fiscal 2011 financial results on Thursday, March 10, 2011.
In conjunction with the company's earnings announcement, the company
will be holding its Fiscal 2010 annual and special meeting of
shareholders. Patheon representatives will provide a brief overview of
Fiscal 2010 results and Fiscal 2011 first quarter results as part of
the meeting and will take questions from those investors in attendance
and, via the Webcast, from analysts and institutional investors who are
not able to attend the meeting. Presentation slides will be posted to
Patheon's Web site prior to the meeting which will begin at 10:00 a.m.
(EST). The Fiscal 2011 first quarter financial results news release
will be issued at approximately 8:00 a.m. (EST) on Thursday, March 10,
Interested parties are invited to access the live meeting and conference
call, via telephone, in listen-only mode, toll free at 1-888-231-8191
(U.S., including Puerto Rico) and 1-647-427-7450 (Canada and
International). Listeners are encouraged to dial in five to fifteen
minutes in advance to avoid delays. A live audio will also be available
via the web at http://www.patheon.com. (Please note that Windows Media Player or RealPlayer is required).
A telephone replay of the conference call will be available between
Thursday, March 10, 2011 and Thursday, March 17, 2011 by dialling
1-800-642-1687 (toll free) or 1-403-451-9481, and by entering identification number
45029866, followed by the number key. The conference call will also be
archived at http://www.patheon.com.
Patheon Inc. (TSX: PTI) is a leading global provider of contract
development and manufacturing services to the global pharmaceutical
industry. The company provides the highest quality products and
services to approximately 300 of the world's leading pharmaceutical and
biotechnology companies. Its services range from preclinical
development through commercial manufacturing of a full array of dosage
forms including parenteral, solid, semi-solid and liquid forms.
Patheon uses many innovative technologies including single-use
disposables, liquid-filled hard capsules and a variety of modified
The company's comprehensive range of fully integrated Pharmaceutical
Development Services includes pre-formulation, formulation, analytical
development, clinical manufacturing, scale-up and commercialization.
Patheon can take customers direct to clinic with global clinical
packaging and distribution services and Patheon's Quick to Clinic™
programs can accelerate early phase development projects to clinical
trials while minimizing the consumption of valuable API. The company's
integrated development and manufacturing network of 11 facilities, and
eight development centers across North America and Europe, enables
customer products to be launched with confidence anywhere in the world.
SOURCE Patheon Inc.
For further information:
Ms. Wendy Wilson
Investor Relations and Corporate Communications
Tel: (919) 226-3313